AR126215A1 - Proceso novedoso - Google Patents
Proceso novedosoInfo
- Publication number
- AR126215A1 AR126215A1 ARP220101651A ARP220101651A AR126215A1 AR 126215 A1 AR126215 A1 AR 126215A1 AR P220101651 A ARP220101651 A AR P220101651A AR P220101651 A ARP220101651 A AR P220101651A AR 126215 A1 AR126215 A1 AR 126215A1
- Authority
- AR
- Argentina
- Prior art keywords
- hexahydro
- ethyl
- sulfonamide
- carbamoyl
- piperidine
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- OHIFQOUPTWBQLE-UHFFFAOYSA-N CCN1CCC(CC1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12 Chemical compound CCN1CCC(CC1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2CCCc12 OHIFQOUPTWBQLE-UHFFFAOYSA-N 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- ZVGHRKGPUUKBPP-UHFFFAOYSA-N 1,2,3,5,6,7-hexahydro-s-indacene Chemical class C1=C2CCCC2=CC2=C1CCC2 ZVGHRKGPUUKBPP-UHFFFAOYSA-N 0.000 abstract 1
- GPGBNMNANZFYBU-UHFFFAOYSA-N CCN1CCC(CC1)S(N)(=O)=O Chemical compound CCN1CCC(CC1)S(N)(=O)=O GPGBNMNANZFYBU-UHFFFAOYSA-N 0.000 abstract 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 abstract 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- SMXMELMJCICPJG-UHFFFAOYSA-N piperidine-4-sulfonamide Chemical compound NS(=O)(=O)C1CCNCC1 SMXMELMJCICPJG-UHFFFAOYSA-N 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/98—Nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a productos intermedios y procesos útiles para preparar 1-etil-N-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)piperidina-4-sulfonamida y sales de esta. La presente invención se refiere además a 1-etil-N-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)piperidina-4-sulfonamida y sales de esta cuando se preparan mediante tales procesos y composiciones farmacéuticas asociadas y usos para el tratamiento y prevención de enfermedades y trastornos médicos, más especialmente por inhibición de NLRP3. Reivindicación 1: Un proceso para preparar 1-etil-N-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)-carbamoil)piperidina-4-sulfonamida o una sal de esta, que comprende la etapa de poner en contacto 1-etil-4-piperidinasulfonamida de fórmula (A) con un derivado de 1,2,3,5,6,7-hexahidro-s-indaceno de fórmula (B) en presencia de un solvente para obtener 1-etil-N-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)piperidina-4-sulfonamida de fórmula (C) o una sal de esta, donde X es un grupo saliente. Reivindicación 32: Una composición farmacéutica que comprende la 1-etil-N-((1,2,3,5,6,7-hexahidro-sindacen-4-il)carbamoil)piperidina-4-sulfonamida o la sal de esta de la reivindicación 8, y un excipiente farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202141028180 | 2021-06-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126215A1 true AR126215A1 (es) | 2023-09-27 |
Family
ID=82458485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101651A AR126215A1 (es) | 2021-06-23 | 2022-06-23 | Proceso novedoso |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240150291A1 (es) |
| EP (1) | EP4359385A2 (es) |
| JP (1) | JP2024524215A (es) |
| KR (1) | KR20240024842A (es) |
| CN (1) | CN118019727A (es) |
| AR (1) | AR126215A1 (es) |
| AU (1) | AU2022300325A1 (es) |
| CA (1) | CA3219597A1 (es) |
| IL (1) | IL308071A (es) |
| MX (1) | MX2023014547A (es) |
| TW (1) | TW202317514A (es) |
| WO (1) | WO2022268935A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL313903A (en) * | 2022-02-15 | 2024-08-01 | Hoffmann La Roche | Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives |
| JP2026502847A (ja) * | 2022-12-23 | 2026-01-27 | エフ． ホフマン－ラ ロシュ アーゲー | Ｎｌｒｐ３阻害剤の調製のためのプロセス |
| WO2025036914A1 (en) | 2023-08-16 | 2025-02-20 | F. Hoffmann-La Roche Ag | Process for the preparation of preparing 1-ethyl-n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)piperidine-4-sulfonamide |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997041119A1 (en) * | 1997-05-02 | 1997-11-06 | Dr. Reddy's Research Foundation | Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
| DK1340757T3 (da) * | 2000-11-16 | 2007-02-12 | Sankyo Co | 1-methylcarbapenemderivater |
| WO2002100833A1 (en) * | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Rho KINASE INHIBITORS |
| NZ535764A (en) * | 2002-04-18 | 2007-10-26 | Schering Corp | 1-(4-piperidinyl) benzimidazolones as histamine H3 antagonists |
| WO2005035495A2 (en) * | 2003-10-08 | 2005-04-21 | Nicholas Piramal India Limited | Fibrinogen receptor antagonists and their use |
| DOP2006000009A (es) * | 2005-01-13 | 2006-08-15 | Arena Pharm Inc | Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina |
| EP2118076B1 (en) * | 2007-02-22 | 2019-09-04 | Merck Serono S.A. | Quinoxaline compounds and use thereof |
| JP5898962B2 (ja) * | 2012-01-11 | 2016-04-06 | 東京応化工業株式会社 | レジスト組成物及びレジストパターン形成方法 |
| EP3383853B1 (en) * | 2015-12-01 | 2020-11-04 | Merck Sharp & Dohme Corp. | Homobispiperidinyl derivatives as liver x receptor (lxr) beta agonists for treating e.g. alzheimer's disease |
| CN120647572A (zh) * | 2017-07-07 | 2025-09-16 | 英夫拉索姆有限公司 | 新颖磺酰胺羧酰胺化合物 |
| GB201712282D0 (en) * | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
| CN111132974B (zh) * | 2017-08-15 | 2023-11-21 | 英夫拉索姆有限公司 | 新颖的磺酰胺羧酰胺化合物 |
| JP2021519337A (ja) * | 2018-03-26 | 2021-08-10 | シー４ セラピューティクス， インコーポレイテッド | Ｉｋａｒｏｓの分解のためのセレブロン結合剤 |
| CN112533913A (zh) * | 2018-05-04 | 2021-03-19 | 英夫拉索姆有限公司 | 新颖化合物 |
| EP3853212A1 (en) * | 2018-09-21 | 2021-07-28 | Novartis AG | Isoxazole carboxamide compounds and uses thereof |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| GB201819083D0 (en) * | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| WO2020157069A1 (en) * | 2019-01-28 | 2020-08-06 | NodThera Limited | Amino heterocyclic compounds and uses thereof |
-
2022
- 2022-06-23 WO PCT/EP2022/067126 patent/WO2022268935A2/en not_active Ceased
- 2022-06-23 TW TW111123528A patent/TW202317514A/zh unknown
- 2022-06-23 JP JP2023578919A patent/JP2024524215A/ja active Pending
- 2022-06-23 MX MX2023014547A patent/MX2023014547A/es unknown
- 2022-06-23 IL IL308071A patent/IL308071A/en unknown
- 2022-06-23 CN CN202280045202.0A patent/CN118019727A/zh active Pending
- 2022-06-23 KR KR1020237044161A patent/KR20240024842A/ko active Pending
- 2022-06-23 EP EP22738569.7A patent/EP4359385A2/en active Pending
- 2022-06-23 AU AU2022300325A patent/AU2022300325A1/en active Pending
- 2022-06-23 AR ARP220101651A patent/AR126215A1/es unknown
- 2022-06-23 CA CA3219597A patent/CA3219597A1/en active Pending
-
2023
- 2023-12-19 US US18/545,711 patent/US20240150291A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023014547A (es) | 2024-04-29 |
| JP2024524215A (ja) | 2024-07-05 |
| US20240150291A1 (en) | 2024-05-09 |
| EP4359385A2 (en) | 2024-05-01 |
| WO2022268935A2 (en) | 2022-12-29 |
| TW202317514A (zh) | 2023-05-01 |
| AU2022300325A1 (en) | 2023-11-02 |
| CN118019727A (zh) | 2024-05-10 |
| AU2022300325A8 (en) | 2023-11-16 |
| CA3219597A1 (en) | 2022-12-29 |
| WO2022268935A3 (en) | 2023-02-02 |
| IL308071A (en) | 2023-12-01 |
| KR20240024842A (ko) | 2024-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126215A1 (es) | Proceso novedoso | |
| AR116753A1 (es) | Proceso de preparación de un derivado de pirazolsulfonilamida | |
| ECSP23054131A (es) | Cocristal de un inhibidor de cdk | |
| AR128931A1 (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| CL2024001022A1 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| MX2018001193A (es) | Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos. | |
| CR20250413A (es) | Compuestos de pirido[4,3–d]pirimidina | |
| AU2022272860A1 (en) | Resorcinol derivative as a pharmaceutically active compound and method of preparation thereof | |
| AR128717A1 (es) | Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2 | |
| FR2430939A1 (fr) | Nouveaux derives d'acides (dl)-16-(phenoxy ou phenoxy substitue)-9-ceto- prostatrienoiques, leur procede de production et medicament les contenant | |
| AR127247A1 (es) | Inhibidores de cdk2 de ciclopentilpirazol | |
| CO2025003090A2 (es) | Compuestos de piridinona sustituida como inhibidores de cbl-b | |
| CO2024015371A2 (es) | Derivados de oxoindolinil amida para inhibir nlrp3 y usos de los mismos | |
| AR128109A1 (es) | Spiros y análogos relacionados para inhibir yap / taz-tead | |
| CR20240536A (es) | Compuestos amido heteroaromáticos útiles en el tratamiento de enfermedades hepáticas | |
| MX2025002817A (es) | Compuestos para el tratamiento del cancer | |
| AR124036A1 (es) | Una composición farmacéutica que comprende una sal farmacéuticamente aceptable de [2-(3-fluoro-5-metanosulfonilfenoxi)etil](propilo)amina, y un fármaco farmacéutico para la enfermedad del parkinson y usos de dicha composición | |
| AR131735A1 (es) | Agentes terapéuticos | |
| MX2023011377A (es) | Derivados de ciclobutilo 1,3-sustituidos y sus usos. | |
| AR128498A1 (es) | Procesos novedosos | |
| UY37745A (es) | Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias | |
| AR131692A1 (es) | Formas cristalinas o sales de un compuesto deuterado | |
| MX2022015532A (es) | Inhibidores selectivos de hdac6 y usos de los mismos. | |
| ECSP22030740A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| US20250066282A1 (en) | Novel analogs of valproic acid and methods of medical treatment using the same |